Overview

Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS

Status:
Completed
Trial end date:
2018-10-08
Target enrollment:
Participant gender:
Summary
Phase 1, open-label study of BHV-0223 in ALS.
Phase:
Phase 1
Details
Lead Sponsor:
Biohaven Pharmaceuticals, Inc.
Collaborator:
Cognitive Research Corporation